ASPEN PHARMACARE HOLDINGS LIMITED - Trading Statement

Trading Statement

Aspen Pharmacare Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number 1985/002935/06)
Share code: APN & ISIN: ZAE000066692
("Aspen")



Trading statement
Aspen’s shareholders are hereby advised that diluted normalised headline earnings
per share from continuing operations, headline earnings per share (“HEPS”) and
earnings per share, for the 12 months ended 30 June 2012, are expected to exceed
those reported in the comparative period, ended 30 June 2011, by the following
ranges:

                 Measure                            Range                   Notes
Diluted normalised HEPS from continuing           18% to 24%                  1
operations
HEPS                                              21% to 27%
Earnings per share                                4% to 10%                   2


Notes:


1. Diluted normalised HEPS from continuing operations comprises diluted HEPS
   from continuing operations adjusted for transaction costs, restructure costs and
   foreign exchange gains on transaction accounting.

2. The growth in earnings per share has been reduced as a result of capital profits
   on the disposal of discontinued businesses and products in the present year being
   lower than in the prior year.


The financial results on which this trading announcement is based have not been
reviewed or reported on by Aspen`s external auditors.

Aspen`s audited results for the year ended 30 June 2012 are scheduled to be
published on SENS on 12 September 2012.

Durban
30 August 2012

Sponsor: Investec Bank Limited

Date: 30/08/2012 10:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.